The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study.
article
OA: green
CC0
⤵ 10 in-corpus citations
Abstract
BACKGROUND: Progestin has been used for symptomatic treatment of adenomyosis, although its effect on the immune system has not been studied. The aim of this study was to investigate the changes of macrophage and natural killer (NK) cell infiltration in tissues obtained from women with adenomyosis who did or did not receive oral progestin dienogest. MATERIALS AND METHODS: In this randomized controlled clinical trial study, 24 patients with adenomyosis who required hysterectomy were enrolled. Twelve patients received dienogest 28-35 days before surgery, and the other 12 patients were not treated with any hormones. The endometrial and myometrial tissue samples were immediately collected after hysterectomy, and immunohistochemistry for a macrophage marker (CD68) and a NK cells marker (CD57) was performed. RESULTS: The number of CD57 cells was significantly increased in endometrial glands of the treated group compared to the untreated group (P=0.005) but not in stroma in the endometrium of the treated patients (P=0.416). The difference in the number of CD68 cells was not statistically significant between treated and untreated groups in the endometrial glands (P=0.055) or stromal tissues (P=0.506). CONCLUSION: Administration of oral progestin dienogest to patients with adenomyosis increased the number of uterine infiltrating NK cells in glandular structure of eutopic endometrium. The differential effects of progestin on NK cells depended on the site of immune cell infiltration. The effects of oral progestin on uterine NK cells in adenomyosis have the potentials to be beneficial to pregnancies occurring following discontinuation of treatment in terms of embryo implantation and fetal protection (Registration number: TCTR20150921001).
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (33)
- A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system via openalex
- Adenomyosis: Review of the Literature via openalex
- Adenomyosis: the pathophysiology of an oestrogen-dependent disease via openalex
- Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy via openalex
- Cytokine Profiling in the Eutopic Endometrium of Adenomyosis During the Implantation Window After Ovarian Stimulation via openalex
- Decreased expression of killer cell inhibitory receptors on natural killer cells in eutopic endometrium in women with adenomyosis via openalex
- Diagnosis of adenomyosis: a review. via openalex
- Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis via openalex
- Different HLA-DR expression in endometriotic and adenomyotic lesions: correlation with transvaginal ultrasonography findings via openalex
- Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats via openalex
- Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis via openalex
- Is adenomyosis an immune disease? via openalex
- Myofibroblasts Are Evidence of Chronic Tissue Microtrauma at the Endometrial-Myometrial Junctional Zone in Uteri With Adenomyosis via openalex
- Peritoneal natural killer cytotoxicity and CD25+CD3+ lymphocyte subpopulation are decreased in women with stage III–IV endometriosis via openalex
- The pathophysiology of endometriosis and adenomyosis: tissue injury and repair via openalex
- W2089336237 via openalex
- W2026199494 via openalex
- W2110232771 via openalex
- W2112160387 via openalex
- W2025633250 via openalex
- W2124080049 via openalex
- W2010035488 via openalex
- W2147838205 via openalex
- W2005347029 via openalex
- W1989952066 via openalex
- W2165782596 via openalex
- W1979822374 via openalex
- W2416443245 via openalex
- W2469348810 via openalex
- W2472392548 via openalex
- W2029675712 via openalex
- W141728048 via openalex
- W2046867627 via openalex
Cited by (10)
- Individualized conservative therapeutic strategies for adenomyosis with the aim of preserving fertility 2023
- Endometrial receptivity in adenomyosis and the role of signaling pathways in the pathogenesis of the disease (literature review) 2022
- GRIM19 downregulation-induced pyroptosis of macrophages through NLRP3 pathway in adenomyosis 2021
- Interaction of M2 macrophages and endometrial cells induces downregulation of GRIM-19 in endometria of adenomyosis 2020
- Adenomyosis: clinical aspects, impact on fertility and pregnancy outcome 2020
- Assessment of the results of comprehensive examination in patients with adenomyosis 2019
- The role of steroid receptors in the pathogenesis of adenomyosis in the presence of concomitant endometrial pathology in postmenopause 2019
- IMMUNOLOGICAL ASPECTS OF ENDOMETRIOSIS ONSET AND PROGRESSION 2019
- Adenomyosis: focus on therapy 2019
- Minimally invasive treatment of adenomyosis 2018
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0
· commercial use OK